Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06588673 · ClinicalTrials.gov registry record · NA

Art Therapy in Progressive Supranuclear Palsy

A NA study of Progressive Supranuclear Palsy, sponsored by Vanderbilt University Medical Center.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT06588673 is a NA study of Progressive Supranuclear Palsy that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 10 participants, below the 451-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06588673, a NA study of Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Our aim is to study the effect of art therapy for people with PSP, with a focus on alleviating the symptoms associated with PSP, enhancing the overall quality of life for patients, and reducing caregiver stress. Overall, through our collaborative efforts on this study, we hope to unlock the benefits of art therapy for this vulnerable patient population, ultimately improving their overall well-being and enhancing their quality of life.

Interventions

  • OTHER Art Thrapy

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-01-14
Est. Completion 2026-12-02
Phase NA

What the Registry Record Tells You About NCT06588673

The ClinicalTrials.gov registry entry for NCT06588673 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 451-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (98% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which Art Thrapy is the first listed.

NCT06588673 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT06588673 about?

NCT06588673 is a clinical study titled "Art Therapy in Progressive Supranuclear Palsy". Our aim is to study the effect of art therapy for people with PSP, with a focus on alleviating the symptoms associated with PSP, enhancing the overall quality of life for patients, and reducing caregiver stress. Overall, through our collaborative efforts on this study, we hope to unlock the benefits...

What is the current status of trial NCT06588673?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-01-14. Estimated completion is 2026-12-02.

What conditions does trial NCT06588673 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT06588673?

The interventions under investigation include: Art Thrapy (OTHER).

Who is sponsoring clinical trial NCT06588673?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06588673 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Progressive Supranuclear Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.